Coeptis Therapeutics Holdings Inc COEP

Alternate Symbol(s): COEPW

Healthcare Biotechnology

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, natural killer cell therapy technology. Its product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological and solid tumors. In addition, the company offers its drugs for acute myeloid leukemia and acute ...

NDAQ:COEP - Post by User

Coeptis Therapeutics Holdings Inc

<< Previous

Bullboard Posts

Next >>

(14)
•••

Post by MasterJediJazz2on Feb 10, 2025 3:09pm

61 Views

Post# 36446510

$COEP $11.81 +4.80% Coeptis Therapeutics NEW Financing!

$COEP Coeptis Therapeutics "We're thrilled to announce the successful closure of our second Series A Preferred financing," said Brian Cogley, CFO of COEPTIS. "This funding is pivotal as we expand our operational capabilities and enhance shareholder value through our new Technology Division. #COEPTIS https://www.marketscreener.com/quote/stock/COEPTIS-THERAPEUTICS-HOLD-146105655/news/COEPTIS-Completes-10-Million-Series-A-Preferred-Financing-Round-Reinforcing-Commitment-to-Technolo-48981330/

User image